Note: This document contains side effect information about blinatumomab. Some of the dosage forms listed on this page may not apply to the brand name Blincyto.
Common side effects of Blincyto include: encephalopathy, seizure disorder, febrile neutropenia, opportunistic infection, balance impairment, confusion, cytokine release syndrome, disorientation, headache, impaired consciousness, tremor, fever, hypotension, increased serum alanine aminotransferase, increased serum aspartate aminotransferase, nausea, neutropenia, speech disturbance, and bacteremia. Other side effects include: pneumonia, sepsis, tumor lysis syndrome, and increased serum bilirubin. See below for a comprehensive list of adverse effects.
Applies to blinatumomab: intravenous powder for solution
Intravenous route (Powder for Solution)
Cytokine Release Syndrome (CRS), which may be life-threatening or fatal, occurred in patients receiving blinatumomab. Neurological toxicities, which may be severe, life-threatening, or fatal, occurred in patients receiving blinatumomab. Interrupt or discontinue blinatumomab as recommended.
Along with its needed effects, blinatumomab (the active ingredient contained in Blincyto) may cause some unwanted effects. Although not all of these side effects may occur, if they do occur they may need medical attention.
Check with your doctor or nurse immediately if any of the following side effects occur while taking blinatumomab:
Incidence not known
Some side effects of blinatumomab may occur that usually do not need medical attention. These side effects may go away during treatment as your body adjusts to the medicine. Also, your health care professional may be able to tell you about ways to prevent or reduce some of these side effects. Check with your health care professional if any of the following side effects continue or are bothersome or if you have any questions about them:
Applies to blinatumomab: intravenous powder for injection
Very common (10% or more): Hypotension (up to 11%)
Common (1% to 10%): Hypertension, tachycardia
Very common (10% or more): Rash (e.g., erythema, rash, erythematous rash, generalized rash, macular rash, maculopapular rash, papular rash, vesicular rash)
Very common (10% or more): Nausea (up to 25%), constipation (up to 20%), diarrhea (e.g., colitis, diarrhea, enteritis, and neutropenic colitis) (up to 20%), abdominal pain (up to 15%), vomiting (up to 13%)
Very common (10% or more): Febrile neutropenia (up to 25%), anemia (up to 18%), neutropenia (up to 16%), thrombocytopenia (up to 11%)
Common (1% to 10%): Leukopenia, leukocytosis, lymphopenia
Uncommon (0.1% to 1%): Capillary leak syndrome
Common (1% to 10%): Hypersensitivity
Very common (10% or more): Cytokine release syndrome (up to 11%), various pathogen infections (44%), bacterial infections (19%), fungal infections (15%), viral infections (13%), increased weight (up to 11%)
Common (1% to 10%): Pneumonia, sepsis, decreased immunoglobulins, increased blood bilirubin, increased gammaglutamyl-transferase, increased liver enzymes
Common (1% to 10%): Cytokine storm
Very common (10% or more): Hypokalemia (up to 23%), hypomagnesemia (up to 12%), hyperglycemia (up to 11%), decreased appetite (up to 10%)
Common (1% to 10%): Hypophosphatemia, tumor lysis syndrome, hypoalbuminemia
Very common (10% or more): Back pain (14%), pain in extremity (up to 12%), bone pain (11%), arthralgia (10%)
Very common (10% or more): Headache (up to 36%), tremor (e.g., resting tremor and tremor) (up to 20%), dizziness (up to 14%)
Common (1% to 10%): Encephalopathy, paresthesia, aphasia, convulsion, memory impairment, cognitive disorder
Uncommon (0.1% to 1%): Speech disorder
Very common (10% or more): Pyrexia (up to 62%), peripheral edema (up to 25%), fatigue (up to 17%), chills (up to 15%), chest pain (up to 11%)
Very common (10% or more): Increased alanine aminotransferase (up to 12%), increased aspartate aminotransferase (up to 11%)
Very common (10% or more): Insomnia (up to 15%),
Common (1% to 10%): Confusion, disorientation
Very common (10% or more): Cough (up to 19%), dyspnea (e.g., acute respiratory failure, bronchial hyperactivity, bronchospasm, dyspnea, dyspnea exertional, respiratory distress, respiratory failure, wheezing) (up to 15%)
Uncommon (0.1% to 1%): Bronchospasm
Medically reviewed by BestRx Medical Team Last updated on 1/1/2020.
Source: Drugs.com Blincyto